

BSW Formulary Update – December 2021 *(Due to operational pressures, the APC December 21 meeting was not held as scheduled. Instead, the following decisions were agreed by a quorate committee via email)*

New and Updated Prescribing Guidelines

- **New** – Primary Care Guidance on the [Use of Rescue Packs in COPD](#)
- **Updated** - [Primary Care COPD Guidance](#)
- **Updated** – [COPD Inhaler Guide](#) Updated
- **Updated** – [Oral Nutrition Supplements \(ONS\) formulary](#)
 - **Foodlink Complete sachets remain first line powdered milkshake style ONS.** Ensure Shake is now second line in place of Aymes Shake. (Ensure Shake offers greater scope of product choice for individuals with dysphagia when compared to Aymes Shake).
 - **Altraplen Energy is now first line ready to drink milkshake style ONS** with Fortisip second line. (Altraplen Energy is more cost effective than Fortisip).

New additions to BSWformulary

- [Trimbow NEXThaler DPI device](#) (Beclometasone/formoterol/glycopyrronium 88/5/9) – added with **GREEN TLS** for use in COPD.
- [Tirbanibulin \(Klisyri®\)10mg/g ointment](#) added with **GREEN TLS** for use in actinic keratosis on face and scalp. Please note the BSW [pathway for treatment of AK](#) is currently being updated to incorporate this new product.
- [Molnupiravir](#) and [Sotrovimab](#) added with **RED TLS** – for use as [COVID-19 treatments](#) via NHSE Covid Medicines Delivery Units (CMDUs) in line with NHSE Commissioning policies

Aligned on BSWformulary

- [Plerixafor 20mg/ml injection](#) – aligned for BSW with **RED TLS**
- [Dexamethasone phosphate injection](#) - aligned with **AMBER TLS**
Note: Presentations available on the BSWformulary are:
Dexamethasone (base) 3.3mg/1ml ampoules [equivalent to 4mg dexamethasone phosphate] and
Dexamethasone (base) 6.6mg/2ml ampoules [equivalent to 8mg dexamethasone phosphate]
To avoid confusion and errors in administering part vials, **dexamethasone for injection dose should be prescribed as dexamethasone PHOSPHATE.**

Other BSWformulary website updates

- [Cyanocobalamin oral tablets](#) – 100microgram strength tablet removed from formulary. This strength is not a licensed medicine nor included in the Drug Tariff and may incur high costs if prescribed on FP10. 50microgram and 1milligram strengths remain on formulary only for prescribing in line with [local guidance](#). For diet related Vit B12 deficiency, patients can be advised to purchase cyanocobalamin OTC in line with [NHSE guidance](#).
- [Insulin lispro sanofi 100units/ml](#) – Note added that in Nov 21, **Sanofi have rebranded from Insulin Lispro Sanofi to Admelog®** (insulin lispro). [Admelog® \(insulin lispro\)](#) is a biosimilar of the rapid-acting insulin Humalog®.

What the BSW CCG formulary team are currently working on

- Working with the BSWCCG Medicines Optimisation Team to review Optimise Profiles in line with BSWformulary. *Please contact bswccg.prescribing@nhs.net in the first instance to clarify TLS status if you have prescribing queries.*
- Reviewing the national Shared Care Agreement (SCA) consultations by [RMOG](#).
- Updating the BSW HRT pathway

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswccg.formulary@nhs.net